Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria
ClinicoEconomics and Outcomes Research · 2026-11 · Volume 18 · 1-10
DOI: 10.2147/ceor.s637548 ↗Kurz gefasst
Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2026-11. Verfasst von Bernhard Schwarz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Karl Landsteiner Society, Center for Public Health, Medical University of Vienna, Vienna, Austria. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Karl Landsteiner Society, Center for Public Health, Medical University of Vienna, Vienna, Austria.
- Global Market Access, Pricing and Medical Affairs, Almirall S.A., Barcelona, Spain.
- Health Economics and Market Access, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany.
Zitieren
APA
Schwarz, B., Solé-Feu, L., Walzer, Y., & Akmaz, B. (2026). Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria. ClinicoEconomics and Outcomes Research, Volume 18, 1-10. https://doi.org/10.2147/ceor.s637548
Vancouver
Schwarz B, Solé-Feu L, Walzer Y, Akmaz B. Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria. ClinicoEconomics and Outcomes Research. 2026;Volume 18:1-10. doi:10.2147/ceor.s637548
BibTeX
@article{Schwarz2026,
author = {Schwarz, Bernhard and Solé-Feu, Laia and Walzer, Yannick and Akmaz, Bülent},
title = {Cost-Effectiveness Analysis of Lebrikizumab versus Dupilumab for Patients with Severe Atopic Dermatitis in Austria},
journal = {ClinicoEconomics and Outcomes Research},
year = {2026},
volume = {Volume 18},
pages = {1--10},
doi = {10.2147/ceor.s637548}
}
EUVIMED